Home/ Supplements/ Omega 3/ TheraNatal Complete Softgel

TheraNatal Complete Softgel

product on market Softgel Capsule Theralogix Nutritional Science Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

The product contains DHA and EPA, omega-3 fatty acids with strong evidence supporting fetal brain and visual development during pregnancy. These ingredients are widely researched for their role in supporting maternal and neonatal health. The evidence coverage for this specific formulation is limited.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for TheraNatal Complete Softgel
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Softgel(s)
Serving Size
91
Servings
Fat/Fatty Acid
Product Type
50%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Calories
5 Calorie(s)
Total Fat
0.5 Gram(s) (1% DV)
Market median: 750.0mg (447 products) 393 studies (A:18, B:204)
Market median: 750.0mg (447 products) 393 studies (A:18, B:204)

Other Ingredients

Fish Oil Concentrate Gelatin Glycerin Water, Purified Annatto natural Mixed Tocopherols
Claims

Label Claims — Verification

Unverified Nutrient
Unverified All Other
Info

Product Information

Formulation Notes

The most comprehensive prenatal Methylated folate, 300 mg of DHA, 75 mcg (3,000 IU) of vitamin D3, B6 & choline

Independently content-certified by NSF International

Additional Information

Certified Sustainable Seafood MSC www.msc.org MSC-C-52793

13 week supply 182 tablets + 91 softgels

Metadata

Product Details

DSLD Entry Date2023-02-21
Product TypeFat/Fatty Acid
FormSoftgel Capsule
DSLD ID283003
Data Updated2026-04-11
Research

Research Evidence

495
Research Sources
56
Avg Quality
222
Meta Analysis
104
Clinical Trial
72
Rct
69
Systematic Review
11
Guideline
5
Cochrane Review
5
Regulatory Source
3
Narrative Review
1
Openfda Safety
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Omega-3 fatty acid addition during pregnancy
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Omega-3 fatty acids for depression in adults
Systematic Review The Cochrane database of systematic reviews 2021 PubMed DOI
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Non-immunosuppressive treatment for IgA nephropathy
Meta Analysis The Cochrane database of systematic reviews 2024 PubMed DOI
A Omega-3 fatty acid supplementation for depression in children and adolescents
Meta Analysis The Cochrane database of systematic reviews 2024 PubMed DOI
A Interventions for fatigue and weight loss in adults with advanced progressive illness
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Motor control exercise for chronic non-specific low-back pain
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
View all evidence for Omega 3 →
Compare

Similar Products

View all Omega 3 products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.